Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

This trial studies a type of advanced breast cancer defined as hormone receptor HR-positive/HER2-negative and classified as non-luminal by gene expression profiling (PAM50). Patients will be treated with trastuzumab deruxtecan (T-DXd) or with physician's choice of CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET). The main purpose of the study is to analyze the efficacy of T-DXd in patients who have HR-positive and HER2-low/ultralow advanced breast cancer classified as non-luminal subtype.

Trial Details

NCT ID
NCT06486883
Phase
PHASE2
Sponsor
MedSIR
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Trastuzumab deruxtecan (T-DXd, DS-8201a)
  • CDK4/6i plus ET
Locations (sample)
  • Brasschaat, Belgium|51.2912,4.49182
  • Mons, Belgium|50.45413,3.95229
  • Woluwe-Saint-Lambert, Belgium|50.84389,4.42912
  • Lyon, France|45.74906,4.84789
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • Patients must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific pro…
  • Female or male patients ≥ 18 years of age at the time of signing ICF.
  • ECOG performance status of 0-1.
  • Minimum life expectancy of ≥ 12 weeks at screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →